- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07733778
Neuroendoscopic Lavage in the Management of Neonatal Intra-ventricular Hemorrhage
Role of Neuro-endoscopic Lavage in the Management of Neonatal Intra-ventricular Hemorrhage
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Neonatal intra-ventricular hemorrhage (IVH) is one of the most common and serious neurological complications affecting premature infants, particularly those born before 32 weeks of gestation and those with very low birth weight. Despite advances in neonatal intensive care, IVH remains a significant cause of mortality and long-term neurodevelopmental disability worldwide (1,2).
The pathogenesis of IVH is closely related to the fragility of the germinal matrix vasculature and the immaturity of cerebral auto-regulation in premature neonates. Fluctuations in cerebral blood flow may result in rupture of these fragile vessels, leading to hemorrhage that can extend into the ventricular system (2,3).
The severity of IVH is commonly classified according to the Papile grading system into four grades. Grades III and IV are associated with the highest rates of morbidity and mortality and carry a significant risk of developing post-hemorrhagic ventricular dilatation (PHVD) and post-hemorrhagic hydrocephalus (PHH) (1,4).
Post-hemorrhagic ventricular dilatation develops as a result of obstruction of cerebrospinal fluid (CSF) pathways by intra-ventricular blood clots and inflammatory debris. Furthermore, blood degradation products trigger inflammatory reactions that impair CSF circulation and absorption, leading to progressive ventricular enlargement and secondary brain injury (3,5).
Several treatment modalities have been proposed for the management of PHVD and PHH, including serial lumbar punctures, ventricular reservoir insertion, ventriculo-subgaleal shunting, external ventricular drainage (EVD), and ventriculo-peritoneal (VP) shunt placement. However, these methods primarily provide CSF diversion without directly removing intra-ventricular blood products that contribute to ongoing inflammation and ventricular dilatation (5,6).
Neuro-endoscopic lavage (NEL) has recently emerged as a promising minimally invasive technique for the treatment of severe neonatal IVH. The procedure involves endoscopic irrigation of the ventricular system with the aim of removing blood clots and inflammatory debris, restoring CSF pathways, and reducing ventricular enlargement. By addressing the underlying pathological substrate rather than merely diverting CSF, NEL may reduce shunt dependency and improve neurological outcomes (6,7).
Recent studies have reported encouraging results regarding the safety and efficacy of neuro-endoscopic lavage in neonates with severe IVH. These studies demonstrated reduction in ventricular size, lower rates of permanent VP shunt insertion, and favorable neurodevelopmental outcomes compared with conventional treatment methods (6,7). Nevertheless, current evidence remains limited, and further prospective studies are required to establish the exact role of neuro-endoscopic lavage in the management of neonatal intra-ventricular hemorrhage.
Therefore, this study aims to evaluate the role of neuro-endoscopic lavage in neonates with intra-ventricular hemorrhage and to assess its impact on ventricular dilatation, shunt dependency, complications, and clinical outcomes.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Ahmed Aboelmagd, Assistant lecturer
- Número de telefone: +20 01099474580
- E-mail: ahmedaboelmagd@aun.edu.eg
Estude backup de contato
- Nome: Mahmoud Gamal, Lecturer
- Número de telefone: +20 01000630887
- E-mail: Mahmoud-gamal@aun.edu.eg
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria
- Neonates aged 28 days or less at the time of presentation.
- Neonates diagnosed with severe IVH with ventricular dilatation (Grade III or IV on Papile classification).
- Written informed consent obtained from parents or legal guardians -
Exclusion Criteria:
- Grade I or Grade II intra-ventricular hemorrhage according to the Papile classification.
- Major congenital brain malformations, like Dandy-Walker malformation and Holoprosencephaly or severe congenital anomalies incompatible with life.
- Neonates with active central nervous system infection (meningitis or ventriculitis).
- Severe coagulopathy not correctable before surgery.
- Refusal of parental or legal guardian consent
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Outro: Neuro-endoscopic lavage in the management of neonatal intra-ventricular hemorrhage
Single arm
|
Neuro-endoscopic lavage for management of neonatal intra-ventricular hemorrhage using normal saline
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Rate of PHVD and permanent VP shunt insertion within the follow-up period after neuro-endoscopic lavage
Prazo: 3 years
|
To evaluate the rate of post hemorrhagic ventricular dilatation and the need for permanent VP shunt after neuroendoscopic lavage for neonatal intra-ventricular hemorrhage
|
3 years
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978 Apr;92(4):529-34. doi: 10.1016/s0022-3476(78)80282-0.
- Ballabh P. Intraventricular hemorrhage in premature infants: mechanism of disease. Pediatr Res. 2010 Jan;67(1):1-8. doi: 10.1203/PDR.0b013e3181c1b176.
- Levene MI, Wigglesworth JS, Dubowitz V. Cerebral structure and intraventricular haemorrhage in the neonate: a real-time ultrasound study. Arch Dis Child. 1981 Jun;56(6):416-24. doi: 10.1136/adc.56.6.416.
- Leijser LM, Miller SP, van Wezel-Meijler G, Brouwer AJ, Traubici J, van Haastert IC, Whyte HE, Groenendaal F, Kulkarni AV, Han KS, Woerdeman PA, Church PT, Kelly EN, van Straaten HLM, Ly LG, de Vries LS. Posthemorrhagic ventricular dilatation in preterm infants: When best to intervene? Neurology. 2018 Feb 20;90(8):e698-e706. doi: 10.1212/WNL.0000000000004984. Epub 2018 Jan 24.
- Schulz M, Buhrer C, Pohl-Schickinger A, Haberl H, Thomale UW. Neuroendoscopic lavage for the treatment of intraventricular hemorrhage and hydrocephalus in neonates. J Neurosurg Pediatr. 2014 Jun;13(6):626-35. doi: 10.3171/2014.2.PEDS13397. Epub 2014 Apr 4.
- Honeyman SI, Martin SC, Lawrence T, Calisto A, Jayamohan J, Magdum S. Neuroendoscopic lavage for the management of neonatal post-haemorrhagic hydrocephalus: A systematic review and meta-analysis. Childs Nerv Syst. 2025 Nov 28;41(1):385. doi: 10.1007/s00381-025-07023-9.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- Endoscopy in neonatal IVhge
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .